Table 1.
Patient and Specimen Parameters and Tumorigenic Virus Detection
| Patient | Sample | Age | Gender | Biopsy Site | UV-exposed | BRAF V600^ | Tx# | Latency (weeks) |
cSCC Morphology* |
HPV genotype^ | HPV genus | MCPyV# |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | P001 | 64 | M | Jaw line, L | Y | E | D | 11 | WF | 65, 80 | β,γ | NP |
| P003 | Forearm, R | Y | D | 11 | WF | 22 | β | N | ||||
| 2 | P005 | 58 | M | Lower leg, R | N | E | D | 50 | WF | ND | NP | |
| 3 | P006 | 73 | M | Shoulder, L | Y | E | V | 12 | KA | 36b | β | NP |
| 4 | P007 | 53 | F | Upper arm, L | Y | E | V | 4.0 | WF | ND | NP | |
| 5 | P008 | 63 | M | Eyelid, L | Y | E | V | 3.4 | WF | ND | NP | |
| P035 | Upper arm, L | Y | V | 11 | C | ND | N | |||||
| P036 | Upper arm, L | Y | V | 19 | KA | RTRX4/HPVX4b, CTR* |
β | N | ||||
| 6 | P010 | 63 | F | Flank, R | N | E | D | 4.6 | KA* | ND | NP | |
| P011 | Upper leg, L | N | D | 4.6 | KA* | ND | NP | |||||
| P012 | Lower abdomen, L | N | D | 4.6 | KA* | ND | NP | |||||
| P013 | Lower back, L | N | D | 4.6 | KA* | ND | NP | |||||
| P014 | Upper back, mid | N | D | 4.6 | KA* | ND | NP | |||||
| P015 | Scapular back, L | N | D | 4.6 | KA* | ND | NP | |||||
| 7 | P024 | 60 | F | Forearm, R | y | E | D+T | 52 | C | ND | Y | |
| P025 | Lower leg, R | N | D+T | 52 | C | 17 | β | N | ||||
| 8 | P040 | 63 | M | Upper forehead, L | Y | E | V | 12.0 | C | FA132 | β | N |
| P041 | Shoulder, R | Y | V | 12.0 | C | ND | Y | |||||
| 9 | P062 | 61 | M | Lateral neck, L | Y | E | V | 54 | C | 38, 17, FA14 | β | N |
| P067 | 62 | Chest, R | N | V | 77 | C | ND | N | ||||
| P069 | Upper leg, R | N | V | 62 | C | 17, 80 | β | N | ||||
| P070 | Chest, R | N | V | 64 | KA | 38, 76 | β | Y | ||||
| P071 | Lower leg, L | N | V | 64 | WF | 38, 105, 143, SIBX18 | β | N | ||||
| P073 | Lower leg, R | N | V | 65 | KA | 17, 24, 38, 124 | β | N | ||||
| 10 | P102 | 51 | M | Shoulder, L | Y | E | V | 28 | C | 17, 38 | β | N |
| 11 | P112 | 57 | M | Upper leg, L | Y | E | V | 16 | C | 17, 38, FA14 | β | N |
| P113 | Upper back, mid | N | V | 16 | C | 17, 22, 38, 111 | β | N | ||||
| 12 | P137 | 59 | F | Leg, L | Y | E | V | 19 | KA | 38, 111 | β | N |
| 13 | P144 | 70 | M | Back | N | E | D | 9.6 | C | 17, 151 | β | N |
| 14 | P151 | 64 | M | Lower leg, L | N | E | D+T | 28 | C | 7, 17, 38 | β,α | N |
| P153 | Upper arm, R | Y | D+T | 52 | C | 17, 22,38 | β | N | ||||
| 15 | P172 | 56 | M | Chest, L | N | E | V | 16 | WF | 17, 24, 38, 111 | β | N |
| P173 | Shoulder, L | Y | V | 16 | WF | 17, 38 | β | N | ||||
| 16 | P184 | 57 | F | Upper leg, R | N | E | V | 5.9 | WF | 38, FA7/FA162 | β | N |
| P187 | 58 | Ant. mandible, R | Y | V | 25 | KA | ND | Y | ||||
| 17 | P201 | 68 | M | Forearm, L | Y | E | V | 9.0 | C | SIBX20, vs42-1 | β | N |
| P202 | Lower leg, L | N | V | 9.0 | KA | ND | N | |||||
| P208 | Upper arm, R | Y | V | 21 | C | 110 | β | N | ||||
| P211 | Upper arm, L | Y | V | 24 | C | 17 | β | N | ||||
| P216 | Upper leg, R | N | V | 27 | C | 17, 38, 111 | β | Y | ||||
| P217 | Lower leg, R | N | V | 27 | KA | 111 | β | Y | ||||
| 18 | P220 | 83 | M | Face, temple, L | Y | E | V | 5.4 | WF | 15 | β | N |
| P235 | Upper back, R | N | V | 39 | KA | 23, 24 | β | N | ||||
| P237 | 84 | Face, cheek, R | Y | V | 46 | KA | SIBX20, vs42-1 | β | N | |||
| 19 | P238 | 70 | F | Lower leg, L | N | K | D+T | 4.3 | KA | 22, 38 | β | N |
| P239 | Lower leg, L | N | D+T | 4.3 | KA | 120 | β | Y | ||||
| 20 | P252 | 62 | M | Knee, L | N | E | V | 24 | C | 38, 111 | β | Y |
| P261 | Forehead, L | Y | V | 32 | KA | 38 | β | N | ||||
| 21 | P263 | 74 | M | Scalp, L | Y | E | V | 1.0 | WF | 24, 38, 111, DL231, FA14, VS20-4 |
β | N |
| P265 | Scalp, vertex | Y | V | 6.1 | WF | 38, 49, DL231, VS20-4, | β | N | ||||
| P269 | Forearm, R | Y | V | 24 | WF | 38, 111 | β | N | ||||
| P270 | Forearm, R | Y | V | 25 | WF | 38 | β | N | ||||
| 22 | P281 | 55 | M | Back, L | N | E | V | 13 | C | CRT-22*, VS42-1 SE68/KC49 |
β | N |
| P282 | Scalp, occiput | Y | V | 13 | C | 17, 38 | β | N | ||||
| P288 | Back, mid, R | N | V | 32 | KA | 38, 111 | β | N | ||||
| P290 | Upper back, L | N | V | 39 | C | 38 | β | N | ||||
| 23 | P333 | 55 | M | Hand, R | Y | E | V | 11 | KA | 38, 111 | β | N |
| P334 | Upper back, L | N | V | 11 | KA | 17, FA14 | β | N | ||||
| 24 | P335 | 60 | M | Lip, lower cut., L | Y | E | V | 11 | KA | 38 | β | N |
| P340 | Face, preauricular, R | Y | V | 5.6 | KA | 25 | β | N | ||||
| 25 | P353 | 42 | F | Lower leg, R | Y | D | V | 13 | C | ND | N | |
| P354 | Lower leg, L | Y | V | 13 | KA | 17, 76, 143 | β | Y | ||||
| 26 | P364 | 69 | F | Face, infraorbital, R | Y | E | V | 24 | WF | 8, 17, 80, 120 | β | N |
| 27 | P404 | 63 | M | Axilla, R | N | E | V | 16 | KA | 17, 38, 76 | β | N |
| 28 | P441 | 63 | M | Chest | N | E | V | 9.1 | KA | 20, 25, 145, CRT-11*, FA18 |
β | Y |
| P442 | Face, cheek | Y | V | 9.1 | C | 17, 124, FA14, FA15, vs42-1 |
β,γ | Y | ||||
| 29 | P467 | 69 | M | Upper arm, L | Y | R | V | 4.0 | KA | ND | Y | |
| P468 | Clavicle | Y | V | 7.3 | KA | 17, 38, 108 | β | N | ||||
| P469 | Lower leg | N | V | 12 | KA | 111, 124, FA14, SIBX18 | β | Y | ||||
Patient (P) identification sample number; male (M) or female (F) gender; left (L) or right (R) laterality; Ultraviolet (UV)-radiation exposed skin (Y); UV-radiation protected skin (N);
Primary melanoma tumor mutation: BRAF valine at amino-acid 600 (V600) mutated to glutamate (E), aspartate (D), lysine (K), or arginine (R);
Therapy (Tx): V = vemurafenib, D = dabrafenib, D+T = dabrafenib with trametinib.
Histomorphology of conventional (C) cutaneous squamous cell carcinoma (cSCC) with keratoacanthoma (KA) and invasive spindle-SCC (KA*) (ref 8) or with wart-like features (WF). Human papillomavirus (HPV) genotype identification, HPV genus of identified genotypes or not detected (ND); Merkel Cell Polyomavirus (MCPyV) identified: yes (Y), no (N), or not performed (NP).